Euclidean Technologies Management Portfolio holdings
Top Buys
| 1 |
Biogen
BIIB
|
+$2.18M |
| 2 |
Sanmina
SANM
|
+$1.95M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$1.77M |
| 4 |
Pediatrix Medical
MD
|
+$1.74M |
| 5 |
iHeartMedia
IHRT
|
+$1.73M |
Top Sells
| 1 |
Gentex
GNTX
|
+$2.4M |
| 2 |
Insight Enterprises
NSIT
|
+$2.17M |
| 3 |
EGOV
NIC Inc
EGOV
|
+$2.1M |
| 4 |
Sturm, Ruger & Co
RGR
|
+$1.9M |
| 5 |
Valero Energy
VLO
|
+$1.81M |
Sector Composition
| 1 | Consumer Discretionary | 28.05% |
| 2 | Technology | 19.36% |
| 3 | Industrials | 17.67% |
| 4 | Communication Services | 12.9% |
| 5 | Materials | 10.99% |
Similar funds
Euclidean Technologies Management's Q4 2019 Portfolio in Review
As of Q4 2019, Euclidean Technologies Management held 72 positions worth $96.4M, down 9.5% from $107M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Euclidean Technologies Management withdrew a net $18.5M in Q4 2019, closing 13 positions and reducing 37 holdings. Its most notable exit was Gentex, an estimated $2.4M position sold in full.
By sector, the portfolio is most concentrated in Consumer Discretionary at 28% of assets, down from 29% a quarter earlier, followed by Technology and Industrials.
Against the trend, Euclidean Technologies Management opened a new position in Biogen worth $2.33M.
- Euclidean Technologies Management's largest Q4 2019 buy was Biogen: 7,860 shares worth $2.33M.
- Euclidean Technologies Management added most to Dana Inc in Q4 2019, an estimated $714K increase.
- Euclidean Technologies Management's biggest Q4 2019 reduction was NIC Inc, cutting an estimated $2.1M.
- Euclidean Technologies Management fully exited Gentex in Q4 2019, selling an estimated $2.4M.
- Euclidean Technologies Management's ten largest holdings make up 24% of its $96.4M portfolio in Q4 2019.
- Euclidean Technologies Management opened 6 new positions and closed 13 in Q4 2019.
- Euclidean Technologies Management's portfolio value fell 9.5% quarter-over-quarter to $96.4M.
Based on Euclidean Technologies Management's 13F filing for Q4 2019, filed 14 Feb 2020.